Monopar Expands Clinical Team with Appointment of Laura Kelly as Director of Clinical Operations Feb 18, 2021
Monopar Announces First Patient Dosed in its Phase 2b/3 VOICE Trial Evaluating Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC) Feb 16, 2021
Monopar Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Outcomes in Bladder Cancer Feb 11, 2021
Monopar Announces Issuance of Patent Covering Composition of Matter for MNPR-101 in Canada Feb 9, 2021
Monopar Announces Issuance of U.S. Patent Covering Compositions of Matter for a Novel Family of Camsirubicin Analogs Dec 22, 2020
Monopar and NorthStar Announce Selection of uPRIT Candidate for Potential Treatment of Severe COVID-19 Dec 10, 2020
Monopar Announces Initiation of its Phase 2b/3 (VOICE) Trial to Evaluate Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC) Dec 8, 2020
Monopar Announces Issuance of New Patents Broadening Protections For Phase 2b/3 Clinical-Stage Lead Product Candidate Validive® Nov 9, 2020
Monopar Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020 Sep 14, 2020
